Kornimate/medical-research-clean huggingface dataset:
patient descriptors of cancer-related fatigue: a mixed methods pilot study of cancer survivors

Conditions: Cancer; Fatigue

Summary: the purpose of this research study is to better understand how cancer-related fatigue affects patients and how it's discussed with providers. this information will be used to develop an educational resource (visual aid poster) that could help individuals and their providers talk about cancer-related fatigue and which may help individuals better manage this symptom.

this is a mixed methods cross-sectional pilot study. the target population is adults ≥ 18 years of age who have been diagnosed with cancer, have completed anti-cancer treatment more than six months ago, have no current detectable evidence of cancer, and are experiencing cancer-related fatigue. participation in this research will involve completion of a six-minute walk test, survey completion, two virtual video interviews, and potentially one additional virtual interview. the interviews will include two 45 minutes for survivors and one 30-minute interview for clinicians. an additional 30-minute interview will be conducted for each survivor and clinician group.

Eligibility criteria:
inclusion criteria: * ability to comply with study procedures for the duration of the study survivors: * written informed consent and hipaa authorization for release of personal information * ability to read/write, understand and converse in english without the need for an interpreter * men and women aged ≥ 18 years at the time of consent * white or caucasian, black or african american, or hispanic or latino/a * history of at least one survivorship care visit at the department of supportive oncology at the charlotte campus or at the winston-salem campus of ahwfbccc * completed curative treatment \> 6 months ago for any cancer type, with no detectable evidence of cancer * self-reported fatigue score of ≥ 4 on the numerical rating scale clinicians: - currently see oncology patients (any cancer type) for survivorship care at the department of supportive oncology at the charlotte campus or at the winston-salem campus of ahwfbccc exclusion criteria: survivors: * continuing maintenance therapy or other cancer-related treatment (i.e. immunotherapy or hormonal therapy) * history of or current severe or untreated depression * hemoglobin \<11g/dl at last cbc soc lab collection * history/diagnosis of dementia * factors or conditions, for which participation may (1) not be in the best interest or (2) interfere with study assessment results (e.g. medical comorbidities, primary brain tumor/metastases) * no access to internet/wi-fi clinicians: - none
study for participants with advanced, not amenable to surgery, or metastatic lung cancer comparing treatment with pemetrexed + cisplatin + enzastaurin versus pemetrexed + cisplatin + placebo

Conditions: Lung Cancer

Summary: this study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy. the study will be conducted in 2 parts: * part 1 is intended to evaluate safety of pemetrexed + cisplatin + enzastaurin combination chemotherapy * part 2 whose main objective is to compare the efficacy of pemetrexed + cisplatin + enzastaurin versus pemetrexed + cisplatin + placebo. participants to be included in part 2 are those with nonsquamous non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * diagnosis of advanced nsclc not amenable to curative treatment. participants enrolling in part 2 of the study must have the above stated diagnosis of nsclc that is also of nonsquamous histology. * no prior systemic therapies \[chemotherapy, et cetera (etc.)\] or pleurodesis with chemotherapy for this disease * prior radiotherapy is allowed but must be completed at least 2 weeks before study enrollment and participant must be recovered from the acute toxic effects * have a good performance status * participant must sign an informed consent document exclusion criteria: * participant had myocardial infarction occurring less than 6 months before inclusion, uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not controlled by medications * participant is unable to swallow tablets * participant is taking a certain medicine to control seizure activity, called "enzyme inducing antiepileptic drugs" and is not able to stop taking the medicine prior to enrolling in the study * participant is unable to interrupt aspirin and/or other anti-inflammatory agents * participant is unwilling or unable to take vitamin supplementation (folic acid and vitamin b12) or medications to prevent side effects
atrioventricular node ablation in patients with atrial fibrillation and moderate chronic heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to determine whether cardiac resynchronization therapy (crt) is superior to interventricular right ventricle (rv) septal pacing in respect of reverse remodeling (lv esd) and morbidity in patients with less preserved (less than 45%) ejection fraction (ef), persistent/permanent atrial fibrillation (af) who successfully received atrioventricular (av) junction ablation ablation (100% pacemaker dependency)


Eligibility criteria:
inclusion criteria: * age of 18-75 years * chf ii-iii nyha * persistent/permanent af requiring av node ablation * lvef \< 45% * signed informed consent * able to complete all testing required by the clinical protocol exclusion criteria: * myocardial infarction or stroke less than 3 months prior to randomization * patients who require revascularization, radiofrequency ablation of pulmonary veins and substrate of af * the congenital and acquired heart diseases, lv aneurysm, which requires a surgical correction * active inflammatory and autoimmune diseases of a myocardium * the thyrotoxicosis * the diseases that limit life expectancy (cancer, tuberculosis, etc.) * contraindications to anticoagulants administration at chads2\> 2 * uncompliant patients

Keywords: heart failure crt atrial fibrillation av junction ablation
we use recovery time to assess post-dialysis fatigue and we use also two different fatigue scales 1- visual analogue scale 2- fatigue severity scale and we address risk factors of pdf and apply the scales on regular hemodialysis patients in hemodialysis unit of assiut university hospital

Conditions: Post-dialysis Fatigue

Summary: to improve the quality of life of hemodialysis patients and provide better control for post dialysis fatigue in regular hemodialysis patients.

post-dialysis fatigue (pdf) is a prevalent and debilitating symptom among patients undergoing regular hemodialysis, characterized by a persistent sense of physical and mental exhaustion following dialysis sessions this condition adversely affects patients' quality of life, daily functioning, and adherence to treatment regimens .despite its high prevalence, pdf remains under-recognized and inadequately addressed in clinical practice. the etiology of pdf is multifactorial, encompassing physiological, psychological, and lifestyle-related factors. recent studies have identified several predictors of pdf, including sleep disorders, the presence of comorbidities, the number of weekly dialysis sessions, and the duration of hemodialysis treatment . the symptoms and severity of pdf are evaluated using various scales. in cases of pdf, to examine the subjective symptoms of patients themselves, it is useful to utilize patient-based outcomes. however, in conventional pdf studies, the evaluation indices have not been uniform. first, in studies evaluating fatigue after dialysis based on the "time," "frequency," and "intensity" the reliability and validity of the scales were not examined. second, the recovery time is not an index that measures pdf directly but instead an indirect indicator that measures the "time to recover from hemodialysis." third, the fatigue scale does not measure true pdf but rather chronic fatigue experienced by dialysis patients . in that research we use time recovery to assess post-dialysis fatigue and we use also two different fatigue scales visual analogue scale to evaluate fatigue severity and fatigue severity scale in that research we address risk factors of pdf and apply the scales on regular hemodialysis patients in hemodialysis unit of assiut university hospital.

Eligibility criteria:
inclusion criteria: * • end stage renal diseases (esrd) patients who receive hemodialysis 3 times a week for 4 h each time. * \> 20 years of age. * both sexes. * patients with stable clinical examination. * patients who receiving hemodialysis for more than 3 months. * all patients were able to go to the center for hemodialysis on their own. * all patients who accept to share in the research. exclusion criteria: * • ages below 20 years. * patients with severe cardiovascular and cerebrovascular diseases. * mental illness that is difficult to diagnose and treat. * surgery within the past month. * patients with acute infections. * pregnancy. * presence of malignancy. * undergoing fracture treatment, and serious mobility. * patients with eye problems.
neutrophil gelatinase-associated lipocalin concentration in coronary artery disease

Conditions: Coronary Artery Disease; Atherosclerosis

Summary: serum ngal has been described as a biomarker of neutrophil activation and an inflammatory marker which correlates to obesity and its metabolic complications. since neutrophil activation has been implicated in the pathogenesis of coronary artery disease, the investigators hypothesized that serum ngal levels would be higher in patients with cad and that serum concentration would correlate with the extent of cad as documented by coronary angiography, serving as a potential biomarker of the severity of cad.

inflammation is considered to play a major role in coronary artery disease (cad) which accounts for high morbidity and mortality rates in the western world. several lines of evidence support a role for neutrophils in the development of atherosclerosis and its progression. neutrophil gelatinase-associated lipocalin (ngal), also known as lipocalin-2, is a 25-kda secretory glycoprotein that was originally identified in mouse kidney cells and human neutrophil granules. this protein has been used as a marker of neutrophil activation in several studies, while recently it was found to be an inflammatory marker closely related to obesity and its metabolic complications. recently, lactoferrin, a protein which co-localizes with ngal in the specific granules of human neutrophils has been proposed as a more dynamic marker of neutrophil activation compared to the widely used myeloperoxidase in patients with cad. in line with the accumulating evidence, this study is designed to investigate the relationship between serum ngal concentration and the presence or the severity of coronary artery disease according to coronary angiography.

Eligibility criteria:
inclusion criteria: * consenting patients undergoing coronary angiography due to suspected cad based on clinical history and results from non-invasive testing exclusion criteria: * abnormal renal function * any known active inflammatory disease * receiving medical therapy with antibiotics, corticosteroids, immunosuppressive agents

Keywords: atherosclerosis ngal coronary artery disease
continuous glucose monitoring in patients undergoing cardiopulmonary bypass

Conditions: Glucose Metabolism Disorders (Including Diabetes Mellitus)

Summary: the purpose of this research study is to test the accuracy of the dexcom continuous glucose monitoring device during the cardiothoracic surgical procedure and recovery period in the cardiac intensive care unit. readings from the device will be compared with the standard of care blood glucose levels that are obtained during your surgery and postoperatively.

the proposed study would examine 100 adult patients specifically undergoing cardiac surgical procedures with the explicit goal of comparing continuous glucose monitoring accuracy to point-of-care testing, particularly in the setting of physiologic perturbations due to vasopressors, acidosis, and hypothermia. with a large sample size and few stipulations on the included patients, this well-powered study would give broadly applicable guidance regarding continuous glucose monitoring use in this population. the study would establish a pathway to further research regarding optimizing continuous glucose monitoring accuracy, providing earlier detection of out-of-range glucose values, improving the precision of insulin titration, and ultimately improving glucose control in the cardiac surgical population, which may improve patient outcomes, including mortality. this would be the first study to describe intraoperative use of the newest dexcom continuous glucose monitoring device, the g7, which has the shortest available warmup time and may be the most accurate continuous glucose monitoring device on the market.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * undergoing cardiac surgery with cardiopulmonary bypass at atrium health wake forest baptist medical center exclusion criteria: * under 18 years of age * pregnant women * patients with a contraindication to device placement on the posterior arm, including rash, missing extremity, or existing line or device

Keywords: continuous glucose monitoring cardiopulmonary bypass cardiac surgery
risk of post-polypectomy bleeding with prophylactic hemoclipping

Conditions: Post-polypectomy Bleeding; Polypectomy; Elective Colonoscopy

Summary: a randomized trial aimed at determining whether or not hemoclips are effective in preventing post-polypectomy bleeds on polyps that are 10mm in size or greater.


Eligibility criteria:
inclusion criteria: * patients presenting for elective colonoscopy exclusion criteria: * patients in which polypectomy can not be performed safely

Keywords: hemoclip colonoscopy post-polypectomy bleed
a study of tadalafil in men with benign prostatic hyperplasia symptoms who are being treated with alpha blockers

Conditions: Benign Prostatic Hyperplasia

Summary: the purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (bph) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination).


Eligibility criteria:
inclusion criteria: * stable on alpha blocker therapy for the treatment of bph for at least 4 weeks prior to starting the study. * have not taken the following treatments within the indicated duration and agree not to use at any time during the study: 1. all other benign prostatic hyperplasia therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication. 2. overactive bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication. 3. erectile dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication. * if taking finasteride or dutasteride, must have been taking treatment for at least 6 months. exclusion criteria: * currently receiving alpha-blocker therapy for the treatment of hypertension. * history of symptoms associated with orthostasis, including recurrent episodes of dizziness, lightheadedness, loss of consciousness, or syncope. * treated with nitrates for any cardiac conditions. * have had any of the following in the past 90 days: heart attack, also known as a myocardial infarction (mi); heart bypass surgery (called coronary artery bypass graft surgery); had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention). * have problems with kidneys, liver, or nervous system * have uncontrolled diabetes * have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer (psa greater than 10 ng/ml at the start of study). * have had a stroke or a significant injury to brain or spinal cord.

Keywords: prostate bph benign prostatic hyperplasia bph-luts luts phosphodiesterase inhibitors tadalafil alpha blockers
adjunctive treatment of chronic migraine using an oral dental device

Conditions: Chronic Migraine, Headache

Summary: single blinding study comparing fda cleared device for prevention of medically diagnosed migraine pain to placebo.

in order to determine if nocturnal jaw clenching can be an influence on chronic migraine pain, the fda cleared "nti" (nociceptive trigeminal inhibition) device with the indications for use of "for prophylactic treatment of medically diagnosed migraine pain" was compared to a similar device that had no influence on jaw clenching.the hit-6 (headache impact test) score was selected as the outcome measure, as the goal was to focus on improving disability in sufferer's lives, as in chronic migraine, changes in headache days may not be as helpful as improving disability.

Eligibility criteria:
inclusion criteria: diagnosed with chronic migraine at a neurology clinic - exclusion criteria: none -

Keywords: single blinded study
nutrition intervention in older adults at risk of malnutrition

Conditions: Malnutrition

Summary: thailand is one of the fastest aging countries and older adults are at greater risk of having inadequate nutrient intake and malnutrition (undernutrition). in the community setting, malnutrition has been linked to low muscle mass, sarcopenia, increased incidence of disability and functional impairments. the objective of this prospective, multicenter, randomized controlled, open-label, parallel-design study is to determine the effects of an oral nutritional supplement with dietary counseling on body weight, in comparison with dietary counseling alone, in community dwelling older adults at risk of malnutrition.


Eligibility criteria:
inclusion criteria: 1. male or female participant aged ≥60 years at risk of undernutrition. 2. community-dweller. 3. participant is community ambulant. 4. participant does not have any chronic disease(s) or has stable chronic disease(s) at study entry. 5. participant voluntarily signed and dated on an irb approved informed consent form (icf) and provided authorization prior to study participation. 6. participant is able to communicate and follow instructions. 7. participant is able to consume food and beverages orally. 8. participant is willing to refrain from taking non-study oral nutritional supplements. 9. participant is able and willing to follow study procedures and record data in diary and complete forms or assessments as needed. exclusion criteria: 1. participant diagnosed with type 1 or type 2 diabetes. 2. participant has active infectious disease. 3. participant has been diagnosed with severe gastrointestinal disorders. 4. participant has been diagnosed with advanced renal disease or end stage organ or pre-terminal diseases or acute myocardial infarction within the last 30 days from the baseline visit. 5. participant has active malignancy within the last five years, or is in current treatment for malignancy. 6. participant has any condition, which in the investigator's opinion, makes him or her unsuitable for inclusion in the study. 7. participant is taking part in another study that has not been approved as a concomitant study. 8. participant has disorder or other conditions, that may interfere with study product consumption or compliance with study protocol procedures. 9. participant has been diagnosed or known to be allergic or intolerant to milk products. 10. participant has continuous oral nutritional supplement usage for 30 days prior to the baseline visit. 11. participant has been taking herbals, dietary supplements, or medications during the past 30 days prior to the baseline visit that could profoundly affect body weight or appetite. 12. participant has clinically significant ascites, pleural effusion, edema, or dehydration
overactive bladder syndrome

Conditions: Overactive Bladder Syndrome; Enuresis, Nocturnal

Summary: purpose: a lot of etiological factors related to overactive bladder (oab) has been investigated. however, the role of primary nocturnal enuresis (ne), which is characterized with childhood night time incontinence, in the etiology of oab is controversial. this study aims to evaluate the effect of ne in patients diagnosed with oab. metod between january-september 2021, the data of patients who applied to the urology outpatientclinic with oab symptoms were collected. patients with a history of chronic systemic disease, previous medical treatment for oab and who did not accept to join the study were excluded. according to the diagnosis of childhood ne, patients were divided into two groups. demographic data hav been recorded. frequency of incontinence, number of day time void and nocturia were evaluated according to a 3 day voiding diary. inaddition, max. urinary flowr atio (qmax), bladder wall thickness and postvoid residual volüme rates were determined using uroflowmetry and pelvic ultrasound.

a prospective randomized study is a study based on basic urological data. this study aims to evaluate the effect of ne in patients diagnosed with oab.

Eligibility criteria:
inclusion criteria: * overactive bladder syndrome * enuresis nocturna exclusion criteria: * diabetes mellitus, * neurological diseases * bladder outlet obstruction, * active urinary system infection

Keywords: overactive bladder enuresis nocturna treatment etiology
iris- desyne x2 in the iris-des registry

Conditions: Coronary Stenosis; Coronary Occlusion; Coronary Disease

Summary: this study evaluates effectiveness and safety of desyne x2 in routine clinical practice.


Eligibility criteria:
inclusion criteria: * age 19 and more * intervention with desyne x2 drug-eluting coronary stent * agreed with written informed consent form exclusion criteria: * intervention with desyne x2 drug-eluting coronary stent and other drug eluting stent at the same time * life expectancy of 1year and under * cardiac shock

Keywords: pci des real world
the purpose of this study is to determine whether cerebroflo™ evd catheter is effective during the treatment of ivh

Conditions: Intraventricular Hemorrhage; Subarachnoid Hemorrhage

Summary: the primary goal of this study is to assess the occurrence of flushing interventions to address occlusions during the treatment of interventricular hemorrhage (spontaneous primary ivh or secondary ivh due to ruptured aneurysm).

potential study candidates will be screened for inclusion and exclusion criteria after informed consent has been provided by the legally acceptable representative and/or the study candidate. once enrolled in the study, data will be collected from those subjects with elevated intracranial pressure (icp), interventricular hemorrhage, or hydrocephalic shunt infections as a result of the use of the evd catheter. pre-insertion and peri-removal ct scans and neurological assessment data will also be collected. data will be collected for subjects beginning from the time of hospital admission through discharge and followed by the 30 day and 90 day follow up visits.

Eligibility criteria:
inclusion criteria: 1. subject and/or legally authorized representative has reviewed the irb- approved consent form, has been properly consented per the protocol and has documented their consent to participate in the study by signing the irb-approved consent form. 2. subject is ≥ 18 years of age at the time of consent. 3. subjects with intraventricular hemorrhage (spontaneous primary ivh or secondary ivh due to ruptured aneurysm) who have had cerebroflo™ evd catheter(s) placed without complication. 4. subjects who require only one evd catheter at initial admission exclusion criteria: 1. subjects with a scalp infection present. 2. subjects with uncorrectable coagulopathy due to prior administration of anticoagulants at the time the cerebroflo™ evd catheter(s) is placed. 3. subjects known to have a bleeding diathesis. 4. subjects in which the cerebroflo™ evd catheter(s) is placed directly into a hematoma 5. evidence of catheter-associated hemorrhage from insertion of the cerebroflo evd catheter(s) on post-placement ct scan. 6. subject is pregnant

Keywords: interventricular hemorrhage